Compare Abbott Laboratories (ABT) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Indonesia Energy Corporation Limited — how do they compare? Abbott Laboratories trades at $110.9 (market cap $187.95B), while Indonesia Energy Corporation Limited trades at $2.92 (market cap $45.55M). The key difference: Abbott Laboratories is far larger — about 4126.2× Indonesia Energy Corporation Limited's market cap, and Abbott Laboratories pays a 2.32% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| ABT | INDO | |
|---|---|---|
Market Cap | $187.95B | $45.55M |
Sector | Health | Energy |
52-Week High | $136.62 | $6.74 |
52-Week Low | $82.57 | $2.49 |
Enterprise Value | $214.96B | $40.92M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Indonesia Energy Corporation (INDO) trades at $2.89, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company is actively drilling the K-29 well at its Kruh Block, indicating operational progress. Financially, it shows deep losses with a net income margin of -253.4% and negative ROE of -26.95% for 2025, though it beat EPS estimates in Q2 2025. Valuation metrics include a P/S of 21.57 and P/B of 2.32, reflecting high sales multiples amid profitability challenges.
The outlook hinges on successful well outcomes driving future revenue; current analyst consensus is 100% buy, but high execution risks and persistent losses pose significant threats to shareholder value. Investors face volatility from oil price swings and operational delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
